Phenylketonuria
New phenylketonuria research, summarized each month in plain language.
2026 so far: So far in 2026 (January-September), medication-based Phe lowering (sepiapterin, pegvaliase) moved forward. Real-world reports also kept pointing to side effects, life-stage transitions, and access to diet products as major factors in how well Phe control can be maintained. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Sepiapterin results. Moved from head-to-head trial data to early real-world outcomes.
- Pegvaliase in practice. More detail emerged on persistence, side effects, and restarts.
- Diet burden and access. Reports increasingly detailed social burden, caregiver strain, and supply gaps.
- Protein substitute strategies. Short trials tested timing and slow-release formats for substitutes.
- Life-stage control. Observational datasets highlighted adulthood and postpartum as vulnerable periods.
New
September 2026
- Diet supply gaps. UK reports noted repeated gaps in protein substitutes and low-protein foods.
- Sepiapterin early findings. Lower phenylalanine sometimes matched better daily function, but not for all.
- Move to adult care. Phenylalanine levels often stayed similar after transfer to adult care.
August 2026
- Diet and Phe. Higher-protein foods were most linked to higher phenylalanine.
- Slow-release substitute. A slow-release substitute slightly lowered day-long phenylalanine and raised tyrosine.
- Pegvaliase restart. Many adults lowered phenylalanine again after restarting pegvaliase.
- Long-term health. Bone density did not match phenylalanine; quality of life was linked to disability and discrimination.
July 2026
- Phe check frequency. More Phe checks were linked to more results in range.
- Adult Phe control. Routine-care data showed Phe control was harder in adulthood.
- Postpartum Phe control. Phe control often improved in pregnancy, then worsened after birth.
- Sapropterin experience. Sapropterin responders reported higher natural protein tolerance.
June 2026
- Sepiapterin effects. Studies linked sepiapterin with lower blood phenylalanine in some people.
- Daily diet burden. Adults reported more fatigue, stress, and poorer self-rated health.
- Food and formula access. Cost and supply gaps made diet treatment harder for some families.
- Screening false alarms. New approaches may help reduce false-positive newborn PKU screens.
May 2026
- Higher sugar and carbs in children. Some studies described higher carbohydrate and sugar intake in children with PKU.
- More body fat, less muscle in adults. In early-treated adults with PKU, studies reported lower lean mass and higher body fat percentage over time.
- Phenylalanine levels and brain MRI changes. Higher recent phenylalanine levels were linked to more MRI abnormalities in children with PKU.
April 2026
- Pegvaliase: Phe lowering and side effects. Real-world reports found that many people on pegvaliase reached lower phenylalanine (Phe) levels, but side effects (including allergic reactions in some) were common.
- Evening medical food timing. In a short study in children, an evening prolonged-release amino acid formula lowered early-morning Phe compared with a standard formula.
- Parent coaching for feeding goals. A brief parenting program study reported that many families partly or fully met parent-set goals, including PKU feeding goals, by 4 months.
March 2026
- Walking and liver tests. In a small study of some children with PKU, a structured walking routine was linked to better liver-related blood test results.
- At-home urine color test. A prototype urine color test showed similar results to a lab method in a limited set of PKU urine samples.
- Urine chemistry differences. Urine chemical patterns differed between classic PKU, BH4-responsive PKU, and milder hyperphenylalaninemia.
February 2026
- Sapropterin and pegvaliase in practice. Sapropterin benefits were mostly seen in children who clearly responded (often allowing more natural protein), while pegvaliase often lowered phenylalanine but was harder to continue through late adolescence.
- Using medical foods day to day. Casein glycomacropeptide (CGMP) substitutes were used by a minority of patients, with access and day-to-day acceptability influenced by residual phenylalanine concerns and how well products fit into routines.
- What can affect test interpretation. BH4 responsiveness testing appeared to vary with age, timing, and starting phenylalanine, and urine markers differed across PKU types, suggesting additional ways to track nutrition and metabolism.
January 2026
- Sepiapterin vs sapropterin. In a short head-to-head comparison, sepiapterin lowered blood phenylalanine more than sapropterin, and longer follow-up linked sepiapterin with a higher dietary phenylalanine allowance for some participants.
- Adult daily living. Adult follow-up reported stable phenylalanine levels with improved self-reported diet and supplement adherence, while psychiatric conditions were common and associated with higher phenylalanine and lower quality of life.
- Faster phenylalanine tests. A prototype sensor measured phenylalanine from dried blood spots with results close to standard lab testing in eight samples, but it still needs real-world validation.
- Gene editing in mice. Liver-targeted gene editing lowered phenylalanine in mouse models, but the same studies also reported barriers such as unintended edits and animal safety concerns.
Get the monthly update by email
Subscribe here to receive an email when a new monthly phenylketonuria update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).